Reata Pharmaceuticals Stock Return On Equity

Reata Pharmaceuticals fundamentals help investors to digest information that contributes to Reata Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reata Stock. The fundamental analysis module provides a way to measure Reata Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reata Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Reata Pharmaceuticals Company Return On Equity Analysis

Reata Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Reata Pharmaceuticals Return On Equity

    
  -1.12  
Most of Reata Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Reata Pharmaceuticals has a Return On Equity of -1.1239. This is 95.31% lower than that of the Pharmaceuticals sector and 96.92% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Reata Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reata Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics of similar companies.
Reata Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Reata Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
CEOs Directory
Screen CEOs from public companies around the world
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios